Another study suggested that DNMT3A-mutated donor clones may enhance graft-versus-leukemia effects, particularly in the absence of post-transplant cyclophosphamide (PTCy), contributing to lower relapse rates and improved progression-free survival. Here, DNMT3A is linked to leukemia.